Industry Reports
Pfizer Completes Acquisition Of Anacor Pharmaceuticals
Pfizer Inc announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without...
Industry Reports
Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
Bristol-Myers Squibb Company will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from...
Industry Reports
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Peregrine Pharmaceuticals, Inc announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series...
Industry Reports
Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Merck known as MSD outside the United States and Canada, announced that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American Society of...
Industry Reports
Thunderbolt Pharma, Inc , Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
Baxalta Incorporated , Velocity Pharmaceutical Development, LLC and Astellas Pharma Inc announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights to the Astellas BAFF/APRIL dual antagonist program through an asset purchase agreement. The BAFF/APRIL dual...
Industry Reports
Merck Co Inc Announces Third-Quarter 2016 Dividend
Merck announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record...
Industry Reports
Merck Increases Sales and Earnings in Q1 Following Sigma-Aldrich Acquisition
Healthcare and Life Science drive Group organic sales growth (+4.7%) Sigma-Aldrich acquisition fuels sales (+20.5%) and EBITDA pre exceptionals (+27.0%) Integration of Sigma-Aldrich proceeding according to plan Net financial debt lowered by around € 600 million Merck confirms...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
